MindWalk Holdings Corp. (HYFT) Stock Price & Analysis

MindWalk Holdings Corp. (HYFT) closed at USD 1.4 on Thursday, October 15, 2026, up 2.19% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 1.37; the Oct 15, 2026 session ranged USD 1.34–1.4 on volume of 139,915 shares. Market capitalization is $65.96M, with a 52-week range of USD 0.99–2.99 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.

Also available as compact Markdown for AI agents: nexqual.com/HYFT.md

Key facts (HYFT)

Analysts (HYFT)

Consensus Buy (mean 2.00 on a 1–5 scale), 3 analysts; mean target USD 4.33 (low 3, high 5).

Total return (dividends reinvested) (HYFT)

1Y (from 2025-10-16)5Y (from 2021-10-11)
Total return-14.6%-78.7%
S&P 500 (SPY)+18.1%+85.1%
Per year-14.7%-26.6%
Volatility (annualized)89.9%95.5%
Max drawdown-63.3% (Jan 2026→Mar 2026)-94.8% (Oct 2021→Feb 2025)

Key Statistics (as of October 16, 2026 at 05:21 UTC)

PriceUSD 1.4
Change▲ 2.19% (up)
Previous CloseUSD 1.37
OpenUSD 1.38
Day RangeUSD 1.34 – 1.4
52-Week RangeUSD 0.99 – 2.99
Volume139,915 shares
Market Cap$65.96M
ExchangeNCM

Technical Analysis (HYFT)

Nexqual's technical model rates HYFT "NEUTRAL" based on 3 bullish and 2 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.

Overall SignalNEUTRAL
RSI (14)49.16 (neutral)
vs SMA50Above (USD 1.37)
MACD0.02 (positive)

Analyst Ratings (HYFT)

Wall Street analysts rate HYFT "Buy" based on 3 analysts, with a mean price target of USD 4.33 (range USD 3–5), per Nexqual as of October 16, 2026 at 05:21 UTC.

Consensus RatingBuy
Analyst Count3
Mean TargetUSD 4.33
High TargetUSD 5
Low TargetUSD 3
Buy / Hold / Sell3 / 0 / 0

Earnings (HYFT)

Next Earnings Date2026-09-14
Revenue Estimate$4.29M

Recent Earnings History

QuarterActual vs Estimate
2026-07-31USD -0.09 vs est -0.05 ▼ miss
2026-04-30USD -0.06 vs est -0.05 ▼ miss
2026-01-31USD -0.06 vs est -0.04 ▼ miss
2025-10-31USD -0.05 vs est -0.02 ▼ miss

Source: Nexqual, October 16, 2026 at 05:21 UTC.

Financials & Fundamentals (HYFT)

Total Revenue$16.23M
Revenue Growth (latest quarter, YoY)+21.30%
Gross Margin+60.79%
Operating Margin-159.86%
Profit Margin-105.20%
ROE-123.66%
Debt / Equity0.5
Current Ratio1.84
Total Cash$7.62M
Total Debt$3.48M

Source: Nexqual, October 16, 2026 at 05:21 UTC.

Financial Health Score (HYFT)

Nexqual rates MindWalk Holdings Corp.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:21 UTC.

GrowthCritical — Revenue -37% YoY (annual), sharp decline
ProfitabilityCritical — Heavily loss-making — early-stage company
Balance SheetSolid — CAD 8M cash vs CAD 3M debt, net cash position
Cash FlowWeak — Operating cash flow -CAD 12M (TTM)
EfficiencyCritical — ROE -124%, ROA -36.4%

Ownership (HYFT)

Insider Ownership+9.14%
Institutional Ownership+9.29%
Shares Outstanding47.11M
Float42.75M
Short % of Float+1.52%

Source: Nexqual, October 16, 2026 at 05:21 UTC.

Leadership (HYFT)

MindWalk Holdings Corp. is led by Jennifer Lynne Bath, CEO, President & Non-Independent Director, per Nexqual as of October 16, 2026 at 05:21 UTC.

CEO, President & Non-Independent DirectorJennifer Lynne Bath
Chief Financial OfficerRichard Scott Areglado (age 61)
Vice President of Commercial ServicesKari Graber
Vice President of Innovative SolutionsShuji Sato
Chief Technology OfficerDirk Van Hyfte

Major Backers & Investors (HYFT)

Notable institutional backers of MindWalk Holdings Corp. include Ingalls & Snyder LLC, Susquehanna International Group, LLP, Renaissance Technologies, according to Nexqual as of October 16, 2026 at 05:21 UTC.

Active Investors

InvestorStake
Ingalls & Snyder LLC6.5%
Susquehanna International Group, LLP1.11%
Renaissance Technologies0.46%
Marshall Wace LLP0.29%
Bank of Montreal /CAN/0.17%

Index Funds (Passive)

FundStake
BlackRock0.64%

Source: Nexqual, October 16, 2026 at 05:21 UTC.

Peers & Related Stocks

SymbolNamePriceChange
RYTMRhythm Pharmaceuticals, Inc.USD 87.97▲ 1.57%
BLTEBelite Bio, IncUSD 152.62▲ 0.49%
IOVAIovance Biotherapeutics, Inc.USD 14.72▲ 1.52%
PRAXPraxis Precision Medicines, IncUSD 248.24▲ 2.01%
IONSIonis Pharmaceuticals, Inc.USD 44.12▲ 4.11%
SYRESpyre Therapeutics, Inc.USD 80.1▼ 0.44%

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt